review team, and panel members are listed in Supplementary Appendix 5, available on the Arthritis Care & Research website at http://online libr ary.wiley.com/doi/10.1002/acr.24596/ abstract Several guiding principles, definitions, and assumptions were established a priori (Table 1 RESULTS/RECOMMENDATIONS The recommendations are based on a set of 81 PICO questions. The literature review initially identified 22,971 manuscripts (for the full set of PICO questions covering both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on the amount of data